FDA Approved: IGALMI — Original Application (BioXcel Therapeutics, Inc.)

View source ↗

Summary

FDA approves IGALMI (dexmedetomidine) by BioXcel Therapeutics for the acute treatment of agitation in adults with schizophrenia or bipolar I or II disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Bipolar Ii Disorder
• Schizophrenia

Drugs mentioned

• IGALMI (DEXMEDETOMIDINE)

Snippet

ORIG AP for IGALMI (DEXMEDETOMIDINE)